Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PharmaDiagnostics rakes €2.5m in series B

This article was originally published in Clinica

Executive Summary

PharmaDiagnostics, a Belgian company specialising in label-free screening technology, has raised €2.5m ($3.5m) in its second round of venture financing. The funds came from firm's existing shareholders, with Capital-E leading the round. Vinnof, the PhD Partnership and Allegro Investment Fund also contributed. Zellik-based PharmaDiagnostics said it will use the new capital to commercialise existing assays – it expects to close at least one deal in the fourth quarter – and further develop new products from its platform screening technology. While all other label-free technologies require expensive, specialised equipment which restricts their applications and compound throughput, PharmaDiagnostics' plasmon resonance technology can be used in assays for both small molecule antibody screening and characterisation, incorporates simple mix-and-read protocols and can be applied in high throughput applications.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044486

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel